737799-50-7 Usage
General Description
(R)-5,5-Dimethyl-3-(pyridin-3-ylsulfonyl)-thiazolidine-4-carboxylic acid is a thiazolidine carboxylic acid derivative with potential anti-inflammatory and hypoglycemic activities. It is a member of the thiazolidinedione class of drugs, which are used in the treatment of type 2 diabetes. Thiazolidinediones work by increasing the sensitivity of cells to insulin, thereby improving glucose uptake and reducing blood sugar levels. The pyridin-3-ylsulfonyl group of this compound is thought to enhance its anti-inflammatory properties, potentially making it useful in the treatment of conditions characterized by chronic inflammation. This chemical may hold promise as a therapeutic agent for both diabetes and inflammatory diseases. Additionally, it can be used as a building block in organic synthesis for the generation of novel thiazolidine carboxylic acid derivatives with improved pharmacological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 737799-50-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,3,7,7,9 and 9 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 737799-50:
(8*7)+(7*3)+(6*7)+(5*7)+(4*9)+(3*9)+(2*5)+(1*0)=227
227 % 10 = 7
So 737799-50-7 is a valid CAS Registry Number.
737799-50-7Relevant articles and documents
PREPARATION OF POLYMER CONJUGATES OF THERAPEUTIC, AGRICULTURAL, AND FOOD ADDITIVE COMPOUNDS
-
Page/Page column 80-81, (2010/11/25)
Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.
IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS
-
Page/Page column 60; 75-77, (2010/11/25)
Disclosed are compounds of the f ormula : and the pharmaceutically acceptable salts thereof wherein the variables A, n, R5, R21-R24 and Q are defined herein. These compounds bind VLA-4. Certain of these compound also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
